Forest announced that the FDA has designated its investigational drug, ceftazidime/avibactam, a Qualified Infectious Disease Product (QDIP) for complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP).
RELATED: Infectious Diseases Resource Center
Ceftazidime/avibactam is a combination broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam, formerly NXL104) to treat Gram-negative infections, including extended-spectrum beta-lactamases and Klebsiella pneumoniae carbapenemases that are resistant to existing therapies.
Ceftazidime/avibactam is currently in Phase 3 trials to investigate the efficacy in treating hospitalized patients with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), both of which are serious Gram-negative bacterial infections.
For more information call (800) 678-1605 or visit FRX.com.